期刊文献+

HPLC法在泊沙康唑及其15种异构体杂质拆分中的应用 被引量:5

Application of High Performance Liquid Chromatography in the Resolution of Posaconazole and Its Fifteen Isomeric Impurities
原文传递
导出
摘要 建立了可同时测定泊沙康唑中15种异构体(14个立体异构体和1个位置异构体)杂质的HPLC法。采用Chiral MD(2)-RH色谱柱(4.6 mm×250 mm,5 μm),流动相为水∶乙腈∶二乙胺(48∶52∶0.1),流速为0.6 ml/min,柱温为30 ℃,检测波长为260 nm。结果显示,14个立体异构体以5个信号出峰,泊沙康唑与15种异构体杂质之间的分离度均符合要求;15种异构体在0.3~12.0 μg/ml内线性关系良好;方法回收率为91.6%~102.7%;检测限为0.09~0.11 μg/ml,定量限为0.28~0.32 μg/ml,均小于0.05%(报告限度)。本方法操作简便,专属性高,可准确测定泊沙康唑原料药及其肠溶片中15种异构体杂质的含量。 An HPLC method was established for the determination of fifteen isomers in posaconazole,including fourteen stereoisomers and one regio-isomer.A Chiral MD(2)-RH column(4.6 mm×250 mm,5 μm) was used with the mobile phase of water∶acetonitrile∶diethylamine(48∶52∶0.1).The flow rate was 0.6 ml/min,the column temperature was 30 ℃,and the detection wavelength was 260 nm.The results showed that the fourteen stereoisomers appeared as five peaks and the resolutions between peaks of posaconazole and these fifteen isomeric impurities all met the requirements.Their linear ranges were 0.3-12.0 μg/ml and the recoveries were in the ranges of 91.6%-102.7%.The detection limits for the fifteen impurities were 0.09-0.11 μg/ml,and the quantification limits were 0.28-0.32 μg/ml,both limits were less than 0.05%(reporting limit).This method was simple to operate and had high specificity,which could accurately determine the contents of fifteen isomeric impurities in posaconazole and its enteric-coated tablets.
作者 孙井龙 游凤 倪冬胜 单冰冰 赵宜香 SUN Jinglong;YOU Feng;NI Dongsheng;SHAN Bingbing;ZHAO Yixiang(Nanjing Huawe Medicine Technology Group Co.Ltd.,Nanjing 210046)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2021年第3期395-399,共5页 Chinese Journal of Pharmaceuticals
关键词 泊沙康唑 手性拆分 高效液相色谱法 异构体杂质 posaconazole chiral separation high performance liquid chromatography isomeric impurity
作者简介 孙井龙(1980-),男,高级工程师,从事药品质量的分析与研究。Tel:13851298688,Email:sjlsjlong@126.com。
  • 相关文献

参考文献3

二级参考文献22

  • 1廖永卫,陈卫平.手性药物与单一对映体药物的发展[J].国外医药(合成药.生化药.制剂分册),1996,17(1):9-17. 被引量:8
  • 2Vehreschild J J, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with a- cute myelogenous leukaemia (AMID : a 6 year experience of the Cologne AML cohort [J]. J Antimicrob Chemother, 2010,65(7) : 1466-1471.
  • 3Sanchez-Ortega I, Patino B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posacon- azole vs itraconazole in allogeneic blood and marrow trans- piantation[J]. Bone Marrow Transplant, 2011,46(5) : 733- 739.
  • 4Winston DJ, Bartoni K, Territo MC, et al. Efficacy, safety, and breakthrough infections associated with standard long- term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients[J]. Biol Blood Marrow Trans- plant, 2011,17(4) :507-515.
  • 5Zoller E, Valente C, Baker K, et al. Development, clinical u- tility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections[J]. Drug Des DeveI T her, 2010,4:299- 311.
  • 6Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet[J], Br J Haematol, 2011,153(6):681-697.
  • 7Walsh TJ, Raad I, Patterson TF, et aI. Treatment of inva- sire aspergillosis with posaconazole in patients who are refrae tory to or intolerant of conventional therapy: an externally controlled trial[J]. Clin Infect Dis, 2007,44(1):2- 12.
  • 8Raad II, Hanna HA, Boktour M, et al. Novel antifungal a-gents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphoteriein B alone or in combination with caspofungin [J]. Leukemia, 2008,22 (3) 496-503.
  • 9Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity[J]. Am J Health Syst Pharm, 2009,66(3) :225-236.
  • 10Greenberg RN, Mullane K, van Burik JA, et al. Posacon- azole as salvage therapy for zygomyeosis[J]. Antimicrob A gents Chemother, 2006,50 ( 1 ) : 126-133.

共引文献28

同被引文献39

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部